TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23261916

Group type: EXPERIMENTAL
Intervention: Cognitive therapy group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Telephone intervention group
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 239
Study: 21489882

Group type: EXPERIMENTAL
Intervention: Circumcision of HIV-infected men (intervention group)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Circumcision of HIV-infected men (control group)
Number of subjects: 474
Study: 18266544

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 86
Study: 15906909

Group type: COMPARATOR
Intervention: Standard PN (A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PN + glutamine (B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PN + omega-3-FA (C)
Number of subjects: 105
Study: 12765295

Group type: COMPARATOR
Intervention: Factor VII genotype (R353Q)
Number of subjects: 374

Group type: COMPARATOR
Intervention: HVR4 polymorphism
Number of subjects: 374

Group type: COMPARATOR
Intervention: Factor II (G20210A) mutation
Number of subjects: 374

Group type: COMPARATOR
Intervention: Factor V (G1691A) mutation
Number of subjects: 374
Study: 10475716

Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg, p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diazepam (2 mg, p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg, p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (received nothing)
Number of subjects: 20
Study: 8703521

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 12
Study: 1387866

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Hepatitis B hyperimmune globulin (HBIG)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Vaccine plus HBIG
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 6149939

Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: bisoprolol 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 8

Group type: COMPARATOR
Intervention: terbutaline up to 3.5 mg
Number of subjects: 8
Study: 31639160

Group type: EXPERIMENTAL
Intervention: Video-assisted class
Number of subjects: 87
Study: 30424482

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (NZBC) - 600 mg total (two capsules of 300 mg each containing 35% blackcurrant extract)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study: 27374222

Group type: EXPERIMENTAL
Intervention: High oleic canola/DHA oil blend (CanolaDHA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional canola oil (Canola)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Corn/safflower oil blend (CornSaff)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Flax/safflower oil blend (FlaxSaff)
Number of subjects: 84

Group type: COMPARATOR
Intervention: High oleic canola oil (CanolaOleic)
Number of subjects: 84
Study: 25233157

Group type: EXPERIMENTAL
Intervention: Revision surgery for tibial nonunion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Reamed nail treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Critical-sized defect
Number of subjects: 37
Study: 22714001

Group type: EXPERIMENTAL
Intervention: 3 mg daclatasvir
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mg daclatasvir
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 60 mg daclatasvir
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20500832

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 17312304

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 7145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7145

Group type: EXPERIMENTAL
Intervention: Tamoxifen (during active treatment)
Number of subjects: 7145

Group type: EXPERIMENTAL
Intervention: Tamoxifen (after treatment)
Number of subjects: 7145

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 7145
Study: 12716266

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard treatment (Fluoxetine or Nortriptyline)
Number of subjects: 183
Study: 11134880

Group type: EXPERIMENTAL
Intervention: Chiroflex C10 IOL
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Chiroflex C11 IOL
Number of subjects: 107
Study: 9552825

Group type: EXPERIMENTAL
Intervention: Bifluorid 12 (CaF2 6% and NaF 6%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (NaF 6%)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (Bifluorid 12 and Control)
Number of subjects: 25
Study: 1588150

Group type: EXPERIMENTAL
Intervention: PRP-OMP (Hib capsular polysaccharide linked to the outer membrane protein complex of Neisseria meningitidis)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HbOC (Hib oligosaccharide covalently linked to the nontoxic mutant diphtheria toxin CRM197)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Unconjugated Hib capsular polysaccharide
Number of subjects: 2
Study: 3898780

Group type: EXPERIMENTAL
Intervention: Benexol B12
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cronassial
Number of subjects: 40
Study: 28711384

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Radical radiotherapy (RT) alone
Number of subjects: 158
Study: 27110603

Group type: EXPERIMENTAL
Intervention: Papilla preservation crown-lengthening procedure (PPCL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Apically positioned flap with buccal approach (APF-B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Apically positioned flap with buccal and palatal approach (APF-BP)
Number of subjects: 30
Study: 24595864

Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 3521

Group type: COMPARATOR
Intervention: Conventional monitoring (IPE)
Number of subjects: 3521
Study: 22037349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5202

Group type: EXPERIMENTAL
Intervention: Weight loss (≥7.5% body weight)
Number of subjects: 5202

Group type: EXPERIMENTAL
Intervention: Weight gain (mean +4.0±6.1 kg) with pioglitazone
Number of subjects: 5202

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 5202
Study: 21031576

Group type: EXPERIMENTAL
Intervention: Transdermal therapy with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19007923

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for perfectionism
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for BN
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15994746

Group type: EXPERIMENTAL
Intervention: Individualized GH treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fixed-dose GH treatment
Number of subjects: 59
Study: 11986111

Group type: EXPERIMENTAL
Intervention: Short wavelength automated perimetry (SWAP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Frequency doubling technology perimetry (FDT)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pattern electroretinography (PERG)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Test battery of SWAP and PERG P1N2-amplitude
Number of subjects: 152

Group type: COMPARATOR
Intervention: SWAP and FDT
Number of subjects: 152
Study: 10703945

Group type: EXPERIMENTAL
Intervention: Cancer patients (CD123+ and CD11c+ cells)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cancer patients with distant organ metastases (CD123+ and CD11c+ cells)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 40
Study: 8699994

Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 50 micrograms/kg/minute
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 75 micrograms/kg/minute
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 100 micrograms/kg/minute
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous ATP (all doses)
Number of subjects: 14
Study: 1928853

Group type: EXPERIMENTAL
Intervention: T3 and hydrocortisone (100 mg hydrocortisone intravenously, 2 or 4 micrograms T3 every hour or half hour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study: 6281143

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study: 31958548

Group type: EXPERIMENTAL
Intervention: Repeated stimulation at short inter-trial intervals (ITIs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Long inter-trial intervals (ITIs)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: First acceleration-deceleration of HR
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Second acceleration-deceleration of HR
Number of subjects: 56
Study: 30743314

Group type: EXPERIMENTAL
Intervention: Voxelotor 900 mg for 15 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Voxelotor (various doses: 100, 400, 1000, 2000, or 2800 mg) single dose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Voxelotor (300, 600, or 900 mg) multiple doses for 15 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Voxelotor in SCD patients (1000 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Voxelotor (various doses)
Number of subjects: 48
Study: 27932413

Group type: EXPERIMENTAL
Intervention: Extent of coronary artery disease (CAD), NT-proBNP, GDF-15
Number of subjects: 5174

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5174

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 5174

Group type: EXPERIMENTAL
Intervention: cTnT-hs
Number of subjects: 5174

Group type: EXPERIMENTAL
Intervention: NT-proBNP or GDF-15
Number of subjects: 5174
Study: 26551372

Group type: EXPERIMENTAL
Intervention: Computerized local anesthesia (Wand)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional local anesthesia (syringe)
Number of subjects: 100
Study: 24171870

Group type: EXPERIMENTAL
Intervention: Borg Scale
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: NRS + FACES
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Likert Scale
Number of subjects: 73

Group type: COMPARATOR
Intervention: Borg Scale vs NRS + FACES
Number of subjects: 73

Group type: COMPARATOR
Intervention: Subjective ratings vs heart rate
Number of subjects: 73
Study: 22937265

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clozapine plus CBT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thioridazine plus CBT
Number of subjects: 48
Study: 19138379

Group type: EXPERIMENTAL
Intervention: NN1731 (5-30 microg kg(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17656028

Group type: EXPERIMENTAL
Intervention: Family-based therapeutic intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 117

Group type: COMPARATOR
Intervention: Community comparison group (non-maltreated children)
Number of subjects: 117
Study: 15522043

Group type: EXPERIMENTAL
Intervention: Incremental cycle exercise test with respiratory gas analysis
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Test and re-test on two consecutive days
Number of subjects: 25
Study: 11748776

Group type: EXPERIMENTAL
Intervention: Citalopram augmentation (20-40 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No citalopram augmentation
Number of subjects: 19
Study: 9023596

Group type: EXPERIMENTAL
Intervention: VLCD (420 kcal/d)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: VLCD (530 kcal/d)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: LCD (880 kcal/d)
Number of subjects: 93
Study: 8343034

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 15

Group type: COMPARATOR
Intervention: m-CPP (placebo)
Number of subjects: 15
Study: 3717618

Group type: EXPERIMENTAL
Intervention: Lidocaine with 2 mg phenylephrine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lidocaine with 5 mg phenylephrine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lidocaine (control group)
Number of subjects: 65
Study: 30311902

Group type: EXPERIMENTAL
Intervention: As Is mud
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mud with extra Dead Sea salt
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Over‐the‐shelf mud
Number of subjects: 75
Study: 27905884

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg t.i.d. for 3 days
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg b.i.d. for 5 days
Number of subjects: 322
Study: 25286026

Group type: EXPERIMENTAL
Intervention: GXR A.M. (GXR in the morning and placebo in the evening)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: GXR P.M. (placebo in the morning and GXR in the evening)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo (twice-daily placebo)
Number of subjects: 333
Study: 22790893

Group type: EXPERIMENTAL
Intervention: Corset wearing for 6 months (CW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No corset wearing (NW)
Number of subjects: 40
Study: 20221773

Group type: EXPERIMENTAL
Intervention: Maximal voluntary cycling power before exercise (1,075 +/‐ 214 W)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perceived exertion during exhaustive cycling exercise
Number of subjects: 10
Study: 19001772

Group type: EXPERIMENTAL
Intervention: 4 g/d XOS for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 26
Study: 15850081

Group type: EXPERIMENTAL
Intervention: Supine PRBS (room air plus 5% CO2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tilt PRBS (room air plus 5% CO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine Control (room air)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tilt Control (room air)
Number of subjects: 20
Study: 12091259

Group type: EXPERIMENTAL
Intervention: Active nutritional supplements (vitamins, minerals, essential fatty acids)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 11934086

Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low blood alcohol concentration (BAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming alcohol concepts and trait-level NFC
Number of subjects: 0
Study: 9527094

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitroglycerin infusion
Number of subjects: 10
Study: 7867113

Group type: EXPERIMENTAL
Intervention: Group A‐‐'10, 30‐13, 30' approach
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Group B‐‐the subpubic approach
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Group C‐‐subcutaneous ring block
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Group D‐‐a combination of frenulum infiltration and the '10, 30‐13, 30' approach
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Group E‐‐a combination of frenulum infiltration and the subpubic approach
Number of subjects: 250

Group type: COMPARATOR
Intervention: Groups A, B, C, D, E
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Subcutaneous ring block or a combination of dorsal nerve block (using the '10, 30‐13, 30' or the subpubic approach) and infiltration of the frenulum
Number of subjects: 250
Study: 2671200

Group type: EXPERIMENTAL
Intervention: Vinburnin (45 mg iv per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 991148

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (CA) synchronization plus vincristine, prednisone, and L-asparaginase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CA synchronization)
Number of subjects: 0
Study: 31270116

Group type: EXPERIMENTAL
Intervention: Steps Towards Alcohol Misuse Prevention Programme (STAMPP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Education as normal (EAN)
Number of subjects: 105
Study: 27814667

Group type: EXPERIMENTAL
Intervention: Chronic Ankle Instability (CAI) group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 63
Study: 25989482

Group type: EXPERIMENTAL
Intervention: Real LFTMS with TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham LFTMS with TENS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LFTMS alone
Number of subjects: 0
Study: 23106186

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 μg.kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study: 21767840

Group type: EXPERIMENTAL
Intervention: Absorbent pad A
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Absorbent pad B
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control condition (follicular phase)
Number of subjects: 17
Study: 19361897

Group type: EXPERIMENTAL
Intervention: Sodium intake <3 g/day (group 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sodium intake >6 g/day (group 2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 49
Study: 17065975

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 15275792

Group type: EXPERIMENTAL
Intervention: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and a weak oral opioid or morphine (dose ≤90 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and morphine (dose ≥90 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pharmacological therapy only (Control group)
Number of subjects: 60
Study: 10675057

Group type: EXPERIMENTAL
Intervention: Seat pan with radius of curvature 75 cm, back-rest with radius of curvature 30 cm, back-rest inclination of 10 degrees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seat pans with radius of curvatures of 60, 75, 90 and infinity cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Back-rests with radius of curvatures of 30, 60, 90 and infinity cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Back-rest inclinations of 0 degrees, 5 degrees and 10 degrees
Number of subjects: 0
Study: 9070471

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg per kilogram of body weight, max 800 mg, given every six hours for eight doses)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 455
Study: 8363997

Group type: EXPERIMENTAL
Intervention: tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: tropisetron plus dexamethasone (Group B2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: tropisetron plus placebo (Group B1)
Number of subjects: 160
Study: 31844890

Group type: EXPERIMENTAL
Intervention: VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 256

Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: VB-111 and bevacizumab combination
Number of subjects: 256
Study: 28258773

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg administered 1 hour before surgery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 25370526

Group type: EXPERIMENTAL
Intervention: Double-layer purse-string uterine closure (Turan technique)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Classical double-layer uterine closure
Number of subjects: 168
Study: 23204164

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tenofovir DF-emtricitabine (TDF/FTC)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Comparison between ABC/3TC and TDF/FTC
Number of subjects: 269
Study: 21458811

Group type: EXPERIMENTAL
Intervention: 10-week exercise program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 19842230

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy plus surgery (CRTS)
Number of subjects: 1737

Group type: EXPERIMENTAL
Intervention: Concurrent neoadjuvant chemoradiotherapy
Number of subjects: 1737

Group type: EXPERIMENTAL
Intervention: Sequential neoadjuvant chemoradiotherapy
Number of subjects: 1737
Study: 18021949

Group type: EXPERIMENTAL
Intervention: Mock panic attacks as an unconditioned stimulus (UCS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CS(+) (conditioned stimulus associated with panic)
Number of subjects: 59

Group type: COMPARATOR
Intervention: CS(-) (conditioned stimulus not associated with panic)
Number of subjects: 59
Study: 15349535

Group type: EXPERIMENTAL
Intervention: Silastic sheath technique in Indianapolis
Number of subjects: 109

Group type: COMPARATOR
Intervention: Modified silastic sheath technique in London
Number of subjects: 109
Study: 11570941

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of influenza
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Laboratory diagnostic techniques (viral isolation, hemagglutinin inhibition serology, multiplex reverse transcription polymerase chain reaction)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Total symptom scores at baseline
Number of subjects: 1033
Study: 9593030

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dextrin sulfate (D2S)
Number of subjects: 24